136 citations
,
March 1996 in “Journal of the American Chemical Society” This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
19 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism”
70 citations
,
June 1993 in “Biochemistry” This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.
86 citations
,
March 1993 in “Toxicology and Applied Pharmacology” Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
122 citations
,
July 1990 in “Teratology” This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.
193 citations
,
August 1985 in “Endocrinology” This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.